Business Wire

DEWA Organises Virtual WETEX and Dubai Solar Show From 26-28 October 2020

Share

Dubai Electricity and Water Authority (DEWA) will organise the 22nd Water, Energy, Technology and Environment Exhibition (WETEX) and the 5th Dubai Solar Show virtually from 26-28 October 2020. The two exhibitions will provide a new experience for exhibitors to display their products innovatively, through 3D customisable stands to suit each company’s needs. They also will enable meetings, seminars, and workshops using the latest smart technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005413/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

WETEX and Dubai Solar Show, First Ever Carbon Neutral 3D Virtual Exhibition (Photo: AETOSWire)

“For 21 years, WETEX has established its position as one of the largest and most important global water, environment, and energy exhibitions. From our wise leadership, we have learned the importance of turning challenges into opportunities. Due to the precautionary measures implemented in most countries because of COVID-19, WETEX and the Dubai Solar Show 2020 will happen virtually; using DEWA’s state-of-the-art digital infrastructure. This will provide an exceptional experience for exhibitors to reach a larger number of visitors across the world,” said HE Saeed Mohammed Al Tayer, MD & CEO of DEWA, and Founder and Chairman of WETEX and Dubai Solar Show.

Al Tayer explained that WETEX and the Dubai Solar Show provide an outstanding opportunity for public and private companies to reach thousands of participants, officials, and decision-makers in energy, water, renewable energy, environment, and sustainability. They will be able to make deals, build partnerships, and learn about market needs, especially given the increased adoption of solar photovoltaic technology in the UAE and the region.

Dr Yousef Al Akraf, EVP of Business Support and Human Resources of DEWA, and Head of the Sales, Logistics and Sponsorship Committees at WETEX, said that this year’s exhibition is an important opportunity to learn about the latest smart technologies and innovative solutions in renewable energy, water, and sustainability. It will enable visitors to participate in specialised seminars and workshops to meet global experts on the green economy, smart cities, innovation, and sustainable development. He noted that WETEX and the Dubai Solar Show 2019 attracted 2,350 exhibitors and 38,718 visitors from 89 countries.

For more information about WETEX and the Dubai Solar Show, please visit www.wetex.ae.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dubai Electricity and Water Authority

Khuloud Al Ali, +971563974965
Media@dewa.gov.ae

Shaikha Almheiri, +971552288228
Shaikha.almheiri@dewa.gov.ae

Mohammad Almheiri, +971552725291
Mohammad.almheiri@dewa.gov.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye